1. Home
  2. HOWL vs GTBP Comparison

HOWL vs GTBP Comparison

Compare HOWL & GTBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Werewolf Therapeutics Inc.

HOWL

Werewolf Therapeutics Inc.

HOLD

Current Price

$0.37

Market Cap

15.7M

Sector

Health Care

ML Signal

HOLD

Logo GT Biopharma Inc.

GTBP

GT Biopharma Inc.

HOLD

Current Price

$0.38

Market Cap

17.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HOWL
GTBP
Founded
2017
1965
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
15.7M
17.7M
IPO Year
2021
2016

Fundamental Metrics

Financial Performance
Metric
HOWL
GTBP
Price
$0.37
$0.38
Analyst Decision
Strong Buy
Analyst Count
4
0
Target Price
$5.00
N/A
AVG Volume (30 Days)
1.0M
1.3M
Earning Date
05-05-2026
05-15-2026
Dividend Yield
N/A
N/A
EPS Growth
18.40
3.75
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.27
$0.26
52 Week High
$2.23
$2.29

Technical Indicators

Market Signals
Indicator
HOWL
GTBP
Relative Strength Index (RSI) 47.06 41.12
Support Level $0.36 $0.29
Resistance Level $0.76 $0.46
Average True Range (ATR) 0.05 0.05
MACD 0.01 -0.01
Stochastic Oscillator 58.47 27.16

Price Performance

Historical Comparison
HOWL
GTBP

About HOWL Werewolf Therapeutics Inc.

Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions. It is leveraging the proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. It has one reportable segment, which focuses on the discovery and development of cancer therapeutics.

About GTBP GT Biopharma Inc.

GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. The company is engaged in discovering, developing, and commercializing therapeutics from its proprietary product platform across various disease areas, mainly focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platform offers immuno-oncology products designed to treat hematologic malignancies, sarcoma, and solid tumors.

Share on Social Networks: